肺癌患者恶病质的药物治疗与营养支持研究进展 Translated title: Research Progress of Pharmacological Therapy and Nutritional Support for Cachexia in Lung Cancer Patients

Abstract

恶病质是肺癌患者的一种常见并发症，它会加重化疗毒副作用、阻碍治疗计划、削弱化疗反应性、降低生活质量，增加并发症及死亡率，严重危害肺癌患者的生理、心理健康。肿瘤恶病质的发病原因与发病机制都极为复杂，使其治疗具有艰巨性与复杂性。控制肺癌患者的恶病质需要采取抗肿瘤治疗、抑制炎症反应、营养支持、体育锻炼、缓解症状等多种手段，发挥多模式治疗的协同作用对抗肿瘤恶病质的多种机制。迄今为止，学科内已就任何单一疗法都不能控制恶病质的发生发展达成了一致共识。有些疗法取得了一定的研究进展，但需要在充分评估肺癌患者个体特征后结合多模式治疗实施。本文重点综述了肿瘤恶病质的药物治疗与营养支持等干预方法在肺癌患者人群中的应用，并对肺癌患者恶病质控制的研究方向进行展望。

Translated abstract

Cachexia is a common complication in patients with lung cancer. It aggravates the toxic and side effects of chemotherapy, hinders the treatment plan, weakens the responsiveness of chemotherapy, reduces the quality of life, increases complications and mortality, and seriously endangers the physical and mental health of patients with lung cancer. The causes and pathogenesis of tumor cachexia are extremely complex, which makes its treatment difficult and complex. Controlling cachexia in lung cancer patients requires many means such as anti-tumor therapy, inhibition of inflammatory response, nutritional support, physical exercise, and relief of symptoms to exert the synergistic effect of multimodal therapy against multiple mechanisms of tumor cachexia. To date, there has been a consensus within the discipline that no single therapy can control the development of cachexia. Some therapies have made some progress, but they need to be implemented in combination with multimodal therapy after fully assessing the individual characteristics of lung cancer patients. This article reviews the application of drug therapy and nutritional support in lung cancer patients, and looks forward to the research direction of cachexia control in lung cancer patients.